In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir. Saquinavir, lopinavir, and darunavir are potent against wild-type HIV-2 isolates and should be preferred as first-line options for HIV-2-infected patients. Other protease inhibitors are less active against HIV-2 than against HIV-1.
Desbois
Delphine
D
Laboratoire de Virologie, Service de Microbiologie, Hôpital Bichat-Claude Bernard, Paris, France.
Roquebert
Bénédicte
B
Peytavin
Gilles
G
Damond
Florence
F
Collin
Gilles
G
Bénard
Antoine
A
Campa
Pauline
P
Matheron
Sophie
S
Chêne
Geneviève
G
Brun-Vézinet
Françoise
F
Descamps
Diane
D
D000069454:Darunavir; D016333:HIV Protease / Q000187:drug effects; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015498:HIV-2 / Q000145:classification* / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D020128:Inhibitory Concentration 50; D061466:Lopinavir; D008826:Microbial Sensitivity Tests; D010641:Phenotype; D011744:Pyrimidinones / Q000494:pharmacology; D019258:Saquinavir / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; D016333:HIV Protease; D019258:Saquinavir; D000069454:Darunavir